

Bill Summary
2nd Session of the 57th Legislature

Bill No.:	SB 1598
Version:	FS1
Request No.:	3984
Author:	Sen. Rosino
Date:	03/10/2020

Floor Substitute (FS)

The FS for SB 1598 requires every health benefit plan issued after November 1, 2020, to include coverage for auto-antibody and calcium calmodulin dependent protein kinase II cell-based testing for pediatric autoimmune neuropsychiatric disorders associated with streptococcal or other infections in pediatric acute onset neuropsychiatric syndrome. Coverage shall include at least 1 testing panel per year and a maximum billing rate of \$1,000.00 per plan per year. Benefits also shall not include a deductible, co-payment, or coinsurance requirement, regardless of whether the testing provider is within or outside of the network. The measure outlines the requirements for a person to obtain this coverage.

Prepared by: Kalen Taylor